WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ: DGRW)

Ultime notizie per WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:DGRW)

WisdomTree U.S. Quality Dividend Growth Fund

Technology

Industrials

Consumer Defensive

Healthcare

Financial Services

Consumer Cyclical

Energy

Communication Services

Basic Materials

Utilities

Real Estate

The Fund employs a passive management or indexing investment approach designed to track the performance of the Index. The Fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the Index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. Under normal circumstances, at least 80 percent of the Funds total assets (exclusive of collateral held from securities lending) will be invested in constituent securities of the Index and investments that have economic characteristics that are substantially identical to the economic characteristics of such constituent securities.

Microsoft Corp

Apple Inc

Abbvie Inc.

Broadcom Corp - Common Cl A

Johnson & Johnson

Home Depot Inc

Procter & Gamble Company

NVIDIA Corporation

Coca Cola Co.

Pepsico Inc.

Exxon Mobil Corp

Chevron Corp

merck &amp; co inc/nj

Walmart, Inc.

Unitedhealth Group Inc

Procter &amp; Gamble Hygiene &amp; Health Care Ltd.

Philip Morris International Inc

WisdomTree US Quality Dividend Growth Fund

Analyst Color

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Dividends

Specialty ETFs

Economics

Analyst Ratings

Trading Ideas

ETFs

DGRW

iShares Dow Jones Select Dividend Index Fund

SCHD

Un&#39;analisi esperta rivela le migliori strategie per capitalizzare sulla volatilità attraverso strumenti finanziari diversificati.

Dazi di Trump: ecco come trasformare il caos in profitti con questi ETF

WIIM

Shares of cruise stocks are trading lower in sympathy with Norwegian Cruise Line, which missed Q1 earnings and revenue estimates.

Baird analyst David Manthey maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Neutral and lowers the price target from $9 to $8.

News

Price Target

HLMN

Baird Maintains Neutral on Hillman Solns, Lowers Price Target to $8

UBS analyst Eliana Merle maintains CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) with a Buy and lowers the price target from $13 to $12.

CVAC

UBS Maintains Buy on CureVac, Lowers Price Target to $12

Central Japan Railway (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CJPRY#OTC">CJPRY</a>) is looking for FY2026 GAAP EPS of $1.41. sees sales of $11.724 billion.

Guidance

CJPRY

Central Japan Railway Sees FY2026 GAAP EPADS $1.41; Sees Sales $11.724B

YUMC

Yum China shares are trading lower after the company reported Q1 EPS and sales below estimates.

<a href="https://www.ft.com/content/1ae70f6c-6651-46e4-bc14-cfd6befc1474">https://www.ft.com/content/1ae70f6c-6651-46e4-bc14-cfd6befc1474</a>

Politics

General

'US-Ukraine minerals deal hits last-minute hurdle'- Financial Times

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $60 to $58.

ATRC

UBS Maintains Buy on AtriCure, Lowers Price Target to $58

Baird analyst Michael Halloran maintains Franklin Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>) with a Neutral and lowers the price target from $111 to $94.

FELE

Baird Maintains Neutral on Franklin Electric, Lowers Price Target to $94

PODC

LiveOne Expects FY25 Revenues: $112M+, Audio Division: Revenues $108M+ and Adjusted EBITDA $16M+

EXTR

EXTR stock has given up its prior gain. Extreme Networks shares were trading higher after the company reported better-than-expected Q3 results and raised FY25 sales guidance.

UBS analyst Thomas Wadewitz maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Neutral and lowers the price target from $100 to $64.

ARCB

UBS Maintains Neutral on ArcBest, Lowers Price Target to $64

Central Japan Railway (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CJPRY#OTC">CJPRY</a>) reported quarterly earnings of $0.27 per share. This is a 575 percent increase over earnings of $0.04 per share from the same period last year. The company reported $3.04 billion in sales this quarter. This is a 3.15 percent increase over sales of $2.95 billion the same period last year.

Earnings

Central Japan Railway Q4 EPADS $0.27 , Sales $3.04B Up From $2.95B YoY

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Market Outperform and maintains $60 price target.

Reiteration

JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target

UBS analyst Jon Windham maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Neutral and raises the price target from $240 to $250.

UBS Maintains Neutral on Waste Management, Raises Price Target to $250

Baird analyst Michael Halloran maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $75 to $76.

Baird Maintains Neutral on A.O. Smith, Raises Price Target to $76

&nbsp;
Market Cap: $72.1 million
<ul>
<li>Ranked Top 10 DSP</li>
<li>Fiscal Year 2025 Expected Revenues: $112M+, Audio Division: Revenues $108M+ and Adjusted EBITDA* $16M+</li>
<li>Share Buyback: $6 million remaining</li>
<li>B2B Partnerships: Over $50 million</li>
<li>Inbound M&amp;A opportunities for LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) and subsidiaries Slacker Radio and PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>)</li>
</ul>
LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>), an award-winning, creator-first, music, entertainment, and technology platform, announced today that it is exploring strategic options following the $207M Napster sale.

Asset Sales

LiveOne Explores Strategic Options Following $207M Napster Sale

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $217 to $230.

UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $230

Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $652 to $587.

REGN

Baird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $587

JMP Securities analyst Aaron Hecht reiterates Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Market Outperform and maintains $130 price target.

JMP Securities Reiterates Market Outperform on Alexandria Real Estate, Maintains $130 Price Target

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 10 years by 19.77% on an annualized basis producing an average annual return of 29.77%. Currently, Copart has a market capitalization of $58.13 billion. 
Buying $100 In CPRT: If an investor had bought $100 of CPRT stock 10 years ago, it would be worth $1,323.55 today based on a price of $60.17 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746022511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPRT

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Comments

WisdomTree U.S. Quality Dividend Growth Fund

Notizie

Ultime notizie per WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:DGRW)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO